Review of the possible association between thyroid and breast carcinoma

Dong, Lemeng; Lü, Jun; Zhao, Bangbo; Wang, Weibin; Zhao, Yupei

doi:10.1186/s12957-018-1436-0

Cited by 42 publications

(62 citation statements)

References 62 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Environmental factors such as high BMI have demonstrated a positive association between breast and thyroid cancer independently but this is a weak association (1). Several studies also suggest an element of detection or screening bias leading to possible earlier detection of a second malignancy after the diagnosis of the primary malignancy (5,7,8).…”

Section: Discussionmentioning

confidence: 99%

Occult metastatic thyroid cancer diagnosed during breast cancer axillary sentinel node biopsy

Herle

Boyages

Hui³

et al. 2020

Endocrinology, Diabetes &Amp; Metabolism Case Reports

View full text Add to dashboard Cite

Summary In most developed countries, breast carcinoma is the most common malignancy in women and while thyroid cancer is less common, its incidence is almost three to five times greater in women than in men. Since 1966, studies have demonstrated an association between thyroid and breast cancer and despite these studies, the mechanism/s by which they are related, remains unclear. We present a case of a 56-year-old lady who initially presented in 2014 with a screen detected left breast carcinoma but was subsequently found to have occult metastatic thyroid cancer to the axilla, diagnosed from a sentinel node biopsy from the primary breast procedure. The patient underwent a left mastectomy, left axillary dissection and total thyroidectomy followed by three courses of radioactive iodine ablation. Despite this, her thyroglobulin level continued to increase, which was secondary to a metastatic thyroid cancer parasternal metastasis. Breast and thyroid cancer presents metachronously or synchronously more often than by chance. With improving mortality in primary cancers, such as breast and differentiated thyroid cancer, it is likely that as clinicians, we will continue to encounter this association in practice. Learning points: There has been a long-standing observation of an association between breast and thyroid cancer although the exact mechanism of this association remains unclear. Our patient presented with thyroid cancer with an incidental diagnosis from a sentinel node biopsy during her primary breast operation for breast cancer and was also found to have a parasternal distant bony metastasis. Thyroid axillary metastases are generally rare. The interesting nature in which this patient’s metastatic thyroid carcinoma behaved more like a breast carcinoma highlights a correlation between these two cancers. With improving mortality in these primary cancers, clinicians are likely to encounter this association in clinical practice. Systemic therapy for metastatic breast and thyroid cancers differ and therefore a clear diagnosis of metastasis is crucial.

show abstract

Section: Discussionmentioning

confidence: 99%

Occult metastatic thyroid cancer diagnosed during breast cancer axillary sentinel node biopsy

Herle

Boyages

Hui³

et al. 2020

Endocrinology, Diabetes &Amp; Metabolism Case Reports

View full text Add to dashboard Cite

show abstract

“…The overall risk of second primary malignancy (SPM) is increased for DTC survivors both in radioiodine-treated and radioiodine-untreated groups (114,115,116), with a latency period much longer than 5 years. Although radioiodine treatment, especially with cumulative activities higher than 7.4-11.1 GBq, is associated with some increased risk of SPM, DTC alone can also independently confer a higher risk of malignancy that may mandate surveillance (117,118).…”

Section: Monitoring For Side Effects and Secondary Malignanciesmentioning

confidence: 99%

Follow-up of low risk thyroid cancer patients: can we stop follow-up after 5 years of complete remission?

Lamartina

Handkiewicz-Junak

2020

European Journal of Endocrinology

View full text Add to dashboard Cite

Each year, the proportion of thyroid cancer patients presenting with low-risk disease is increasing. The shift in the landscape of thyroid cancer presentation is forcing clinicians to re-evaluate not only management but also surveillance paradigms. During the follow-up, patients are stratified considering their response to treatment and classified into one of the following response categories: excellent, biochemical incomplete, structural incomplete, or indeterminate. These categories reflect a real-time prognosis and thereby substantially influence and personalise disease management. Although at present, no guideline recommends stopping differentiated thyroid carcinoma (DTC) surveillance at any particular time point, the relatively low prevalence of treatment failures in low-risk patients may prompt early discontinuation of surveillance in this subgroup. Therefore, this debate will present an overview of the controversies surrounding the surveillance of low-risk patients with DTC.

show abstract

“…Therefore, thyroid and breast cancer might share some common etiological factors. 12 I-131 is an effective and low-risk therapy modality in well-differentiated thyroid cancer patients post near-total thyroidectomy. Extra thyroidal tumors such as breast cancer are known to be able to uptake 131 I.…”

Section: Resultsmentioning

confidence: 99%

Uptake and effect of radioiodine exposure on SKBR-3 cell lines

et al. 2019

View full text Add to dashboard Cite

Radioiodine has been known as an adjuvant therapy for thyroid cancer. Beside for thyroid cell, radioiodine is reported to be taken up by breast cell. It may be proposed as an alternative for breast cancer therapy. Objective: The study aim was to analyze an uptake of radioiodine and cell proliferation rate of breast cancer cell after the exposure of radioiodine. Methods: This study used SKBR-3 cell line as representative of Human Epidermal Growth Factor Receptor (HER2+) subtype. The cells were planted in DMEM medium added 10% fetal bovine serum (FBS), panstrep 1% and amphotericin B. The cells were grown until 80% confluent and then stripped. Subsequently the cells were sub-cultured on plates 12 and 6 wells respectively for measured uptake of radioiodine and cell proliferation rate after the exposure. Radioiodine uptake was calculated by sum efflux of 125 Iodine (125I) and the amount of uptake after the addition of 95% ethanol. Cell proliferation rate was measured by calculated by using clonogenic assay after iodine-131 (131I) exposure. Results: The average of iodine uptake was 194±50 cpm/106 cell. The average cell proliferation after radioiodine exposure was 54%±5%; Conclusions: Radioiodine is taken by SKBR-3 cells and it reduced cell proliferation rate. This finding shows an opportunity for radioiodine as an alternative therapy for breast cancer. Another studies are needed to understand of cell death the mechanism.

show abstract

Review of the possible association between thyroid and breast carcinoma

Cited by 42 publications

References 62 publications

Occult metastatic thyroid cancer diagnosed during breast cancer axillary sentinel node biopsy

Occult metastatic thyroid cancer diagnosed during breast cancer axillary sentinel node biopsy

Follow-up of low risk thyroid cancer patients: can we stop follow-up after 5 years of complete remission?

Uptake and effect of radioiodine exposure on SKBR-3 cell lines

Contact Info

Product

Resources

About